Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioSpecifics Technologies names new board member
Dr Geller brings to BioSpecifics extensive financial experience with biotechnology companies as he has served for over 15 years as a sell-side analyst and investment banker covering biotechnology
Dr Geller brings to BioSpecifics extensive financial experience with biotechnology companies as he has served for over 15 years as a sell-side analyst and investment banker covering biotechnology
Under PPD’s agreement with Takeda, the submission of the new drug application for alogliptin and Actos does not trigger a milestone payment to PPD. If the new drug
The transaction is structured as a stock-for-stock exchange and in addition, Pharmacopeia stockholders will be entitled to a contingent value right (CVR). The CVR’s will entitle holders under
CardioGen-82 is said to be the only generator-based positron emission tomography (PET) perfusion agent approved by the FDA and reimbursed for the evaluation of coronary artery disease. CardioGen-82
The FDA clearance follows Syneron’s receipt in Europe of CE mark clearance for the Matrix RF. Matrix RF utilizes Syneron’s radio frequency technology to provide effective ablation and
According to Grameen Health, these multiple, independent collaborations will focus on social business models in which the businesses are self-supporting and any profits are re-invested into the system
Center for Molecular Medicine (CMM) is a joint venture between Spectrum Health, a not-for-profit health systems in Michigan, and the Van Andel Research Institute, an independent research institute
The results showed that Ophena significantly improved a broad range of clinical signs of vulvovaginal atrophy (VVA), including petechiae, pallor, friability, vaginal dryness and redness in mucosa. These
In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single doses starting at 400mg. At the 2000mg dose level, it was administered during
Results showed that with Saizen therapy, levels of all biomarkers studied significantly changed between baseline and one month in both Turner syndrome (TS) and growth hormone deficiency (GHD)